In a phase II clinical trial, all the volunteers usually get the same dose. But some phase II studies randomly assign participants to different treatment groups (much like what’s done in phase III trials). These groups may get different doses or get the treatment in different ways to see which provides the best balance of safety and effectiveness.
No placebo (sham or inactive treatments) is used.
The primary endpoint for the Phase 2 Study measured an absolute change from baseline in inflammatory lesions at week 12.
The primary endpoint, all dose groups of BTX 1503 reduced the number of inflammatory lesions from baseline with the highest efficacy obtained for the 5% BTX 1503 QD group (-11.8 lesions). This corresponds to an average percent reduction of 40.54%.
BOT are forerunners to a new frontier with little competition and an amazing team of people.
- Forums
- ASX - By Stock
- BOT
- Ann: Botanix Announces BTX 1503 Data and Progression to Phase 3
Ann: Botanix Announces BTX 1503 Data and Progression to Phase 3, page-144
-
- There are more pages in this discussion • 259 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BOT (ASX) to my watchlist
|
|||||
Last
38.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $687.8M |
Open | High | Low | Value | Volume |
37.5¢ | 38.0¢ | 35.0¢ | $4.519M | 12.27M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 75362 | 37.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
38.0¢ | 326113 | 17 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1500 | 0.385 |
6 | 21289 | 0.380 |
1 | 15233 | 0.370 |
4 | 466054 | 0.365 |
11 | 722617 | 0.360 |
Price($) | Vol. | No. |
---|---|---|
0.375 | 444 | 1 |
0.380 | 289871 | 14 |
0.385 | 220411 | 9 |
0.390 | 723886 | 12 |
0.395 | 530169 | 11 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
BOT (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online